StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.00−0.08 (-0.44%)

Close on Nov 17, 2026Market cap $2.88BP/E –Yield –

Denali Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Denali Therapeutics's pe ratio was 141.2× on Jan 31, 2022.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2022Jan 31, 2022141.2×−42.8
2021Dec 31, 2021184.1×–

More Denali Therapeutics figures

See a number that looks wrong?